https://ultimovacs.com/about-ultimovac

"Ultimovacs is a biotechnology company focused on developing a near universal cancer peptide vaccine UV1 that targets human telomerase reverse transcriptase (known to be expressed in c 85% of cancer types). After successful completion of the Phase I programme, Ultimovacs has initiated a Phase II programme with two clinical trials running.

Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase."  

"Ultimovacs Announces Positive 5-Year Overall Survival Update from Phase I Combination Trial Evaluating Universal Cancer Vaccine UV1 in Metastatic Melanoma"  

"Christmas came a few days early for Ultimovacs as the company was able to announce the initiation of its fourth phase II trial with universal vaccine UV1. The combination study, aimed at head and neck cancer patients indicated to receive checkpoint inhibitor pembrolizumab, will be conducted at 10 sites across Germany and led by renowned principal investigator Prof. Mascha Binder, M.D.”  

" Cancer vaccine with virtually universal potential ....."  

intakt.  

Nachdem drei klinische Studien zum Cancer Vaccine UV1 t fehlgeschlagen sind, hat die Vollversammelung der Aktionäre der Ultimovac eine Verschmelzung mit der privaten Zelluna ASA beschlossen und zum 3.3.2025 umgesetzt.

Die Begründung und der Abschluss für 2024 sowie eine detailierte Beschreibung der innovative TCR-NK Technologie und deren Positionierung in der Zelltherapie Landschaft sind als englisch-sprachiger Webcast verfügbar.